Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects
NCT ID: NCT02923583
Last Updated: 2017-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
243 participants
INTERVENTIONAL
2016-10-31
2017-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
M834
M834 (abatacept biosimilar candidate)
M834
US Orencia®
US-sourced Orencia® (abatacept)
US-Sourced Orencia®
EU Orencia®
EU-sourced Orencia® (abatacept)
EU-Sourced Orencia®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
M834
US-Sourced Orencia®
EU-Sourced Orencia®
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy as determined by medical history, physical examination, vital signs, and 12 lead electrocardiography (ECG) at screening.
3. Body mass index (BMI) between 18 and 32 kg/m2.
4. Body weight between 50.0 and 100.0 kg, inclusive.
5. Has smoked no more than 10 cigarettes, 3 cigars, or 3 pipes/day for at least 1 month prior to screening and is willing to comply with smoking restrictions during confinement at the study center.
6. Willing and able to comply with the requirements of the study.
7. Willing and able to sign a written informed consent.
Exclusion Criteria
2. History of invasive systemic fungal infections (e.g., histoplasmosis, coccidioidomycosis) or other severe opportunistic infections; subjects with well-controlled or mild recurrent or chronic local fungal infections (e.g., tinea versicolor, onychomycosis, athlete's foot) may be included at the discretion of the Investigator.
3. A serious infection (associated with hospitalization and/or required intravenous anti-infectives) within 6 months of study drug administration or a significant infection requiring oral or topical anti-infectives within 4 weeks of study drug administration.
4. Any minor infection within 2 weeks of admission to the clinical unit on Day -1 that, in the opinion of the Investigator, may require systemic therapy or otherwise impact safety or participation in the study.
5. Herpes zoster infection in the last year or more than 1 herpes zoster infections in his/her lifetime.
6. Frequent chronic or recurrent infections (defined as \>3 a year requiring prescribed antibiotic treatment; subjects with \>3 viral upper respiratory infections may be considered based on Investigator discretion).
7. Previous administration of abatacept, belatacept, or biosimilar candidates referencing abatacept or belatacept.
8. Receipt of another recombinant human monoclonal antibody within 6 months prior to dosing in this trial, or within 5 half-lives, or within the expected period of pharmacodynamic effect; whichever is longest.
9. Intake of any study drug in another trial within 3 months prior to dosing in this trial or have received the last dose of an investigational drug \>3 months ago but who are on extended follow-up, or planned dosing of an investigational drug (other than for this study) during the course of this trial.
10. History of alcohol abuse in the past year, or history of regular consumption of alcohol, or unwillingness to comply with the alcohol restrictions outlined.
11. History of drug abuse.
12. Donation of blood within 3 months or blood products (e.g., platelets within 6 weeks, plasma within 7 days) prior to dosing.
13. Use of any prescribed or non-prescribed medication, dietary supplements or herbal medication during the 2 weeks prior to dosing.
14. History of or current congestive heart failure.
15. History of or current signs or symptoms of demyelinating disease including optic neuritis and/or multiple sclerosis.
16. History of any cancer including lymphoma, leukemia, skin cancer and cervical carcinoma in situ.
17. History of immunodeficiency (including those subjects with a positive test for human immunodeficiency virus \[HIV\] I and II at screening) or other clinically significant immunological disorders, or auto-immune disorders. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, metabolic, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders as judged by the investigator.
18. Received a live vaccine within 12 weeks prior to clinic admission (Day -1) or plan to receive a live vaccine during the study (up to and including Day 71).
19. Pregnant or breast-feeding women.
20. Men or women of childbearing potential who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include use of a condom with spermicide and one of the following highly effective methods: stable use of oral contraceptives or other prescription pharmaceutical contraceptive, intrauterine device (IUD); bilateral tubal ligation, vasectomy, additional barrier method \[e.g., diaphragm, cap, sponge\]).
* Contraception is not required for subjects who are abstinent (abstinence should be their preferred and usual lifestyle; contraception should be used as described if subjects stop being abstinent), subjects in exclusive same-sex relationships, and post-menopausal females.
* Postmenopausal women must be amenorrheic for at least 12 months, confirmed by follicle-stimulating hormone (FSH) level \>40 IU/L at screening in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mylan Inc.
INDUSTRY
Momenta Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Candida Fratazzi, MD
Role: STUDY_DIRECTOR
Momenta Pharmaceuticals, Inc.
James Bush, MBChB, PhD, MRCS(Ed), MFPM
Role: PRINCIPAL_INVESTIGATOR
Covance Clinical Research Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Covance Clincal Research Unit Ltd
Leeds, , United Kingdom
Hammersmith Medicines Research (HMR)
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOM-M834-001
Identifier Type: -
Identifier Source: org_study_id